查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球呼吸系統疾病治療市場 - 2022-2029
市場調查報告書
商品編碼
1176600

全球呼吸系統疾病治療市場 - 2022-2029

Global Breathing Disorder Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

呼吸系統藥物是用於治療某些呼吸道或呼吸系統疾病（例如慢性阻塞性肺病和哮喘）的藥物。 這些藥物可減輕炎症並打開呼吸道，使呼吸更順暢。 更多地暴露在空氣污染和灰塵中，以及吸煙的增加將推動這些藥物的採用。

市場動態

呼吸系統疾病藥物市場受到哮喘和慢性阻塞性肺病等呼吸系統疾病患者人數增加、先進技術的興起、研發投資增加以及新興市場醫療基礎設施投資增加的推動。I在這裡。

呼吸系統疾病治療藥物滲透率的提高和研發投資的增加預計將推動市場的增長。

呼吸系統疾病藥物市場受到技術進步、呼吸系統疾病治療需求增加、研發投資激增、慢性呼吸系統疾病（如哮喘、慢性阻塞性肺病、慢性支氣管炎）增加以及新興國家醫療基礎設施的推動。它被驅動通過醫學的進步和使用最新技術改進新藥。 據世界衛生組織稱，慢性阻塞性肺病 (COPD) 影響著全世界近 2 億人。 目前，政府增加用於治療慢性病的資金正在推動市場的增長。 例如，在歐盟，慢性阻塞性肺病的直接成本約佔醫療保健總成本的 6%，佔呼吸系統疾病總成本的近 56%。

技術進步正在增加呼吸系統疾病藥物的採用。 呼吸系統疾病的增加、對治療呼吸系統疾病的支氣管擴張劑和抗生素的認識提高以及政府和私營公司增加醫療保健支出可能會導致基礎設施投資增加，從而推動呼吸系統疾病治療市場。

各種新產品的發布和研究正在為市場的增長做出貢獻。 例如，2022 年 3 月 14 日，諾華旗下的 Sandoz 宣布已成功收購總部位於英國的藥物輸送和醫療器械開發商 Coalesce Product Development Limited。 通過此次收購，Sandoz 獲得了重要的 Coalesse 能力，以幫助建立其現有的呼吸產品組合。

與呼吸系統疾病藥物相關的副作用預計會阻礙市場增長。

全球呼吸系統疾病藥物市場因呼吸系統疾病治療的副作用而受阻。 副作用包括口乾、發抖、頭暈、喉嚨痛或喉嚨發癢、流鼻涕和胃部不適。

關於批准用於治療呼吸系統疾病和支氣管擴張劑相關震顫、神經緊張、心悸和肌肉痙攣等不良事件的藥物的嚴格規章制度阻礙了市場增長。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了積極影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於各種研究，隨著 COVID 病例數量的增加，臨床試驗已經認真開始，因此 COVID 導致呼吸系統疾病治療市場取得了巨大收益。 主要製造商已經啟動了各種研究和臨床試驗。 全球正在發生多項舉措、產品發布、合作和合併，推動了市場的增長。 例如，2021 年 12 月 17 日，安進公司宣布阿斯利康和安進公司的 Tezspire（tezepelumab-ekko）獲得美國食品藥品監督管理局（FDA）的批准，用於 12 歲兒童和成人嚴重哮喘患者的附加維持治療和更老。宣布它是

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 呼吸系統疾病藥物流行率增加
      • 研發費用增加
      • 技術進步的增加
    • 約束因素
      • 與呼吸系統疾病藥物相關的副作用
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章藥物類別

  • 抗菌劑
    • 妥布黴素 (TOBI)
    • 噴他□ (nevpent)
    • 利巴韋林（病毒唑）
  • 腎上腺皮質類固醇
    • 布地奈德
    • 外消旋腎上腺素
  • 支氣管擴張劑
    • 間丙腎上腺素（Alpent）
    • 異丙托銨 (Atrovent)
    • 福莫特羅（表演者）
    • 阿福莫特羅（Brovana）
    • 鹽酸左沙丁胺醇 (Zopenex)
    • 硫酸沙丁胺醇 (Acuneb)
  • 抗組胺劑
    • 扎魯司特
    • 齊拉頓
    • 孟魯司特
  • 呼吸興奮劑
    • 西替利秦
    • 氯雷他定
  • 其他

第八章按功效與作用

  • 慢性阻塞性肺疾病 (COPD)
  • 支氣管哮喘
  • 囊性纖維化
  • 肺動脈高壓
  • 肺癌
  • 過敏性鼻炎
  • 特發性肺纖維化
  • 其他

第 9 章（按銷售渠道）

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • F. Hoffmann-La Roche
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • AstraZeneca
  • GSK plc
  • Abbott Laboratories
  • Amgen Inc.
  • Novartis AG
  • Medtronic plc
  • Dr. Reddy's Laboratories Ltd.
  • Bayer AG
  • Biogen

第13章 DataM

簡介目錄
Product Code: DMPH4725

Market Overview

Breathing disorder drugs are medications used for treating several respiratory or breathing disorders, such as COPD and asthma. These medicines make breathing easier by reducing inflammation and opening the airways. High exposure to air pollution and dust and increased smoking will enhance the adoption of these drugs.

Market Dynamics

The market for breathing disorder treatment is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.

The rising adoption of breathing disorders drugs and increasing investment in research and development are expected to drive the market's growth.

The breathing disorder treatment market is driven by rising advancements in technology, an increase in demand for breathing disorder drugs, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost the market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.

Technological advances have resulted in increasing breathing disorder drugs adoption. The rising number of respiratory disorders, increasing awareness about bronchodilators and antimicrobial drugs for treating respiratory disorders and rising healthcare expenditure by governments and the private sector could lead to higher infrastructure investments and drive the breathing disorder treatment market.

Various novel product launches and research studies contribute to the market's growth. For instance, in March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. Sandoz, with this acquisition, acquired the significant capabilities of Coalesce that can help in building on its existing respiratory medicines portfolio.

The side effects associated with breathing disorder treatment drugs are expected to hamper the market's growth.

The global market for breathing disorder treatment is restrained by the side effects of drugs for breathing disorder treatment. Side effects include dry mouth, tremors, dizziness, irritated or scratchy throat, runny nose and upset stomach.

Stringent rules and regulations for respiratory disorders treatment drugs approval and adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The breathing disorder treatment market has experienced huge profits due to COVID as various research, and clinical trials got started in full swing due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.

Segment Analysis

The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The bronchodilators segment is the highest market holder in the global breathing disorder treatment market. The global breathing disorder treatment market is segmented on the basis of drug class in antimicrobial, corticosteroid, bronchodilator, antihistamines, respiratory stimulants and others. The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.

These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs basically stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), who experienced asthma exacerbations.

Geographical Analysis

North America holds the largest market share in the global breathing disorder treatment market.

North America dominates the global breathing disorder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults suffered from chronic obstructive pulmonary disease (COPD) in the United States in 2020. And 25 million have asthma.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of medications for breathing disorder treatment in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the breathing disorder treatment market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2020, Bayer announced its license agreement and research collaboration with Curadev, a domestic drug discovery firm for discovering novel drug candidates for cardiovascular, lung and inflammatory diseases treatment.

Competitive Landscape

The breathing disorder treatment market is highly competitive with local and global companies' presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Abbott Laboratories, Amgen Inc., Novartis AG, Medtronic plc, Dr. Reddy's Laboratories Ltd., Bayer AG, Biogen and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in February 16, 2022, Mankind Pharma announced that it had signed an acquisition agreement with Dr. Reddy's Laboratories for two brands, Daffy and Combihale. Combihale is utilized for treating chronic obstructive pulmonary disease and asthma.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Arcapta Neohaler: Arcapta Neohaler is the once-daily, 24-hour long-acting beta2-agonist that has been approved for airflow obstruction in COPD patients' maintenance treatment.

Key Development: In November 19, 2020, Novartis announced its exclusive global collaboration and license agreement with Mesoblast for the development, manufacturing and selling of remestemcel-L for acute respiratory distress syndrome (ARDS) treatment, including that associated with COVID-19.

The global breathing disorder treatment market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising adoption of breathing disorder drugs
      • 4.1.1.2. Increasing research and development expenditure
      • 4.1.1.3. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the breathing disorder treatment drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Antimicrobial *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Tobramycin (TOBI)
    • 7.2.4. Pentamidine (Nebupent)
    • 7.2.5. Ribavirin (Virazole)
  • 7.3. Corticosteroid
    • 7.3.1. Budesonide
    • 7.3.2. Racemic epinephrine
  • 7.4. Bronchodilator
    • 7.4.1. Metaproterenol (Alupent)
    • 7.4.2. Ipratropium (Atrovent)
    • 7.4.3. Formoterol (Perforomist)
    • 7.4.4. Arformoterol (Brovana)
    • 7.4.5. Levalbuterol HCl (Xopenex)
    • 7.4.6. Albuterol sulfate (AccuNeb)
  • 7.5. Antihistamines
    • 7.5.1. Zafirlukast
    • 7.5.2. Zileuton
    • 7.5.3. Montelukast
  • 7.6. Respiratory stimulants
    • 7.6.1. Cetirizine
    • 7.6.2. Loratidine
  • 7.7. Others

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Chronic Obstructive Pulmonary Disease (COPD) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Asthma
  • 8.4. Cystic Fibrosis
  • 8.5. Pulmonary Hypertension
  • 8.6. Lung Cancer
  • 8.7. Allergic Rhinitis
  • 8.8. Idiopathic Pulmonary Fibrosis
  • 8.9. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca
  • 12.3. GSK plc
  • 12.4. Abbott Laboratories
  • 12.5. Amgen Inc.
  • 12.6. Novartis AG
  • 12.7. Medtronic plc
  • 12.8. Dr. Reddy's Laboratories Ltd.
  • 12.9. Bayer AG
  • 12.10. Biogen

LIST NOT EXHAUSTIVE

13. Global Breathing Disorder Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Indication
  • 13.3. Contact Us